IPO - Profile

Summary

Overview

Our vision is to improve the lives of patients and families suffering from rare muscle disorders by building the world’s leading muscle-focused, precision medicine company.

At Edgewise, patients are at the core of everything we do. We recognize that for patients with rare and debilitating diseases, every day without an effective treatment is a day too late and we are driven by this urgency to evolve disease knowledge with an aim to develop novel precision medicines for severe and rare disorders driven by muscle dysfunction. Our intimate knowledge of muscle biology More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$16.00 11,000,000 Positive High 5.9%

Offering Team

  • Legal counsel
  • Cooley LLP
  • Auditors
  • KPMG LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 25 Mar, 2021

Offer 26 Mar, 2021

Look Ahead

Lock Up Expiry Sep 26, 2021

IPO Terms

Offer Price $16.00
Offer Size 11M

Market Sentiments

Stock Price